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Abstract
It has been shown that deletion of the chemokine receptor, CXCR4, causes disordered angiogenesis in mouse models. In
the present studies, we examined the distribution and trafficking of CXCR4 in human endothelial cells, tested their responses
to the CXCR4 ligand, SDF-1, and asked whether endothelial cell CXCR4 can serve as a cell surface receptor for the binding
of viruses. The results show that CXCR4 is present on endothelial cells from coronary arteries, iliac arteries and umbilical
veins (HUVEC), but expression was heterogeneous, with some cells expressing CXCR4 on their surface, while others did not.
Addition of SDF-1 caused a rapid decrease in CXCR4 surface expression. It also caused CXCR4-mediated activation of
MAPK, release of PGI2, endothelial migration, and the formation of capillary-like structures by endothelial cells in culture.
Co-culture of HUVEC with lymphoid cells that were chronically infected with a CD4-independent/CXCR4-tropic variant of
HIV-2 resulted in the formation of multinucleated syncytia. Formation of the syncytia was inhibited by each of several
different CXCR4 antibodies. Thus, our findings indicate: (1) that CXCR4 is widely expressed on human endothelial cells ;
(2) the CXCR4 ligand, SDF-1, can evoke a wide variety of responses from human endothelial cells ; and (3) CXCR4 on
endothelial cells can serve as a receptor for isolates of HIV that can utilize chemokine receptors in the absence of
CD4. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chemokines are a family of small (8^13 kDa) se-
creted proteins best known for their ability to cause
leukocyte activation and migration [1,2]. Many of
these e¡ects have been shown to be mediated by a
family of G protein-coupled receptors that includes
at least a dozen members [3,4]. Working through
these receptors, chemokines are able to initiate intra-
cellular signaling and evoke biological responses [3^
8]. In addition, chemokine receptors can serve as co-
receptors for human and simian immunode¢ciency
viruses. For example, CCR5, a receptor for
RANTES, MIP-1K and MIP-1L, has been shown
to be required for infection by some macrophage-
tropic HIV-1 strains and CXCR4, the subject of
the present study, can serve as a fusion co-factor
for some T-cell line adapted HIV-1 [9,10].
Much of what is currently known about chemo-
kines and chemokine receptors has been learned
through studies on blood cells. Because of their lo-
cation bordering the vascular space, endothelial cells
would also be expected to come into contact with
chemokines, as well as HIV and blood cells infected
with HIV. A role for chemokines and chemokine
receptors in endothelial cell biology is suggested by
several reports, including the very striking observa-
tion that deletion of the gene encoding CXCR4 in
mice results in disordered angiogenesis and cardio-
genesis, as well as abnormal lymphopoiesis and
hematopoiesis [11,12] ^ e¡ects that are similar to
those observed in mice lacking the CXCR4 ligand,
SDF-1 [13]. Other reports show that endothelial cells
express the Du¡y antigen/receptor [14,15] and an
IL-8 receptor [16], as well as the membrane-bound
chemokine, fractalkine [17]. It has also been shown
that di¡erent chemokines can stimulate (IL-8) or in-
hibit (PF4) angiogenesis [16,18^20]. Since endothelial
cells stimulated with histamine or TNF-K will secrete
chemokines, including IL-8 and RANTES [17,21^
28], chemokines and their receptors potentially play
a variety of roles in angiogenesis and in£ammation
that involve endothelial cells.
Of the chemokine receptors known to be expressed
on endothelial cells, CXCR4 is one of the most in-
teresting. CXCR4 was previously shown to be ex-
pressed on lymphocytes and monocytes [29,30],
CD34 hematopoietic progenitor cells [31^33] and
most human T- and B-cell lines [34]. CXCR4 is
also present in brain, lung and spleen [35^37] and
was the ¢rst chemokine receptor shown to be a co-
receptor for HIV entry [9]. The only known ligand
for CXCR4 is SDF-1 [38,39]. Two recent reports
have shown that CXCR4 is expressed on human um-
bilical vein endothelial cells (HUVEC) and that ad-
dition of SDF-1 to HUVEC in culture triggers a
small increase in cytosolic Ca [40,41]. It was also
shown that in£ammatory cytokines, such as IFN-Q
and TNF-K a¡ect CXCR4 mRNA levels in HUVEC
[41]. Taken together, with the results of the CXCR4
knockout studies [11,12], these observations suggest
that the SDF-1/CXCR4 ligand/receptor pair plays a
role in endothelial cell biology and that CXCR4 ex-
pression is regulated in part by molecules released in
the in£ammatory process.
Beyond these core observations, however, little is
known about the signaling events and responses that
occur in human endothelial cells following the acti-
vation of CXCR4, or about the fate of the receptor
once it has been activated. Therefore, in the present
studies, we have examined the e¡ects of SDF-1 on
events in endothelial cells further downstream from
receptor activation and compared them with the ef-
fects of activating another G protein coupled recep-
tor that is expressed on human endothelial cells, the
human thrombin receptor, PAR1. We have also ex-
amined the e¡ects of SDF-1 on CXCR4 expression
in endothelial cells and tested responses to SDF-1 in
a model of angiogenesis. Finally, because CXCR4
has been shown to be able to support the entry of
some isolates of HIV into cells that lack CD4, we
also tested whether endothelial cell CXCR4 could
serve as an HIV receptor, despite the fact that endo-
thelial cells do not express CD4 [42^45]. Our ¢ndings
support evolving concepts about the role of SDF-1
and CXCR4 in angiogenesis, hemostasis and in£am-
mation, and suggest that CXCR4 could under some
circumstances function pathologically as a receptor
for HIV.
2. Materials and methods
2.1. Materials
SDF-1K was synthesized at Berlex BioSciences.
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Thrombin was provided by Dr. J. Fenton (New
York State Department of Health, Albany, NY).
The CXCR4 selective monoclonal antibody 12G5
(IgG2a) has been described previously [34], as have
the thrombin receptor antibody, WEDE15 [46,47]
and the CD4 monoclonal antibody #19 [34]. Addi-
tional monoclonal antibodies (all IgG2b) to CXCR4,
44701, 44702, 44708, 44712, and 44717, were pro-
duced by immunizing mice with 3T3 cells that stably
expressed human CXCR4, and were kindly provided
by Dr. Monica Tsang (RpD Systems, Minneapolis,
MN). EH1 (IgG1) and D47 (IgG2a) are reactive with
the HIV-1/Nef protein and HIV-1/LAI gp120, re-
spectively, and were used as negative controls.
2.2. Cell culture
Early passage human umbilical vein endothelial
cells (HUVEC) were prepared from human umbilical
cords as described [48]. Human iliac artery endothe-
lial cells were prepared from healthy vessel sections
removed for transplantation. Sup-T1 cells were
grown in RPMI-1640 medium supplemented with
10% fetal bovine serum (FBS, Gibco).
2.3. Human tissue samples
Human coronary arteries were isolated from hearts
removed from transplant recipients. For immunohis-
tochemistry, replicate 2^3 mm sections were ¢xed by
immersing each sample in either: (1) 100% ethanol
overnight at 21‡C; (2) 10% neutral bu¡ered formalin
overnight at 21‡C; or (3) 4% paraformaldehyde over-
night at 4‡C followed by 15% sucrose for 4 h at 4‡C.
All samples were then embedded in para⁄n and se-
rial sections of 5 mm were cut on ProbeOn Plus
slides for immunohistochemistry studies with the
antibodies indicated. All studies were done with the
approval of the University of Pennsylvania’s Institu-
tional Committee on Studies Involving Human
Beings.
2.4. Fluorescence microscopy
For surface staining of intact cells, endothelial cell
monolayers were washed with ice-cold staining bu¡er
(phosphate-bu¡ered saline (PBS) with 0.02% sodium
azide and 0.2% bovine serum albumin), incubated
with monoclonal antibodies (20 Wg/ml) for 30 min
at 4‡C, washed with staining bu¡er, then incubated
with rhodamine-labeled goat anti-mouse IgG (1:100;
Jackson ImmunoResearch Laboratories) for 30 min
at 4‡C. Cell monolayers were washed with staining
bu¡er, ¢xed with 4% formalin (Polysciences) in 100
mM PIPES, pH 6.8, 2 mM EGTA, 2 mM MgCl2
and 130 mM NaCl. Fixed monolayers were washed
with staining bu¡er, then distilled water, and cover-
slips mounted with Elvanol. For intracellular stain-
ing, cells were ¢xed with 4% formalin (as described
above), permeabilized with 0.2% Triton X-100 in
PBS for 10 min, then blocked for 30 min in 10%
goat serum in PBS. The cells were then incubated
sequentially with CXCR4 monoclonal antibodies,
rhodamine-labeled goat anti-mouse IgG, and £uores-
cein-conjugated anti-human Factor VIII related anti-
gen (1:50; Atlantic Antibodies) diluted in 10% goat
serum in PBS.
2.5. Immunohistochemistry
For immunolabeling, a modi¢cation of the strep-
tavidin^biotin^peroxidase method was performed us-
ing the MicroProbe System (Fisher Scienti¢c, Pitts-
burgh, PA). Isotype matched non-immune mouse
immunoglobulin was used as a control. Brie£y, sec-
tions were depara⁄nized, hydrated in 100 and 95%
ethanol, washed and then treated with 2% normal
horse serum for 20 min at room temperature to
block non-speci¢c binding by the antibody. The
slides were then incubated with the relevant primary
antibodies overnight at 4‡C followed by an addition-
al 1 h at room temperature. After washing, biotiny-
lated anti-mouse serum (Vector Laboratories) at a
1:200 dilution was applied for 60 min at room tem-
perature. The slides were then incubated for 60 min
at room temperature with the streptavidin^biotin
system (Dako) at a 1:50 combined dilution and
visualized with 0.05% (v/v) 3,3P-diaminobenzidine
solution (Sigma) and 0.03% (v/v) H2O2 for 5 min.
After a ¢nal wash, the slides were counterstained
with aqueous hematoxylin and reviewed by two in-
vestigators.
2.6. Flow cytometry
HUVEC, detached with PBS containing 1 mM
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EDTA and 5 mM EGTA, and Sup-T1 cells were
harvested by centrifugation and resuspended in
RPMI-1640 without phenol red at 1U106/ml. After
incubation under the conditions indicated for each
experiment, the cells were placed on ice and incu-
bated with the indicated primary antibody for 20
min. After washing with staining bu¡er, the cells
were resuspended in fetal calf serum and incubated
with a 1:40 dilution of FITC-labeled goat anti-mouse
IgG (BioSource International) and analyzed on a
FACscan £ow cytometer (Becton Dickinson).
2.7. Cytosolic Ca2+
HUVEC were loaded with 5 WM Fura-2/AM (Mo-
lecular Probes, Eugene, OR) in RPMI-1640 without
phenol red for 1 h at 37‡C, then detached from the
culture dishes by incubation for 15 min at 37‡C with
PBS containing 1 mM EDTA and 5 mM EGTA. The
detached cells were washed and resuspended in
RPMI-1640 containing 0.4 mM Ca2, but no phenol
red. After equilibration for 60 min at room temper-
ature, the cells were washed again and resuspended
at 1U106/ml. Changes in the cytosolic free Ca2 con-
centration were measured with an SLM/Aminco
model AB2 £uorescence spectrophotometer [48].
2.8. Prostacyclin (PGI2) formation
PGI2 was measured in the cell culture media as its
stable metabolite, 6-keto-PGF1K, using gas chroma-
tography/mass spectrometry, as previously described
[49,50]. A known amount of internal standard,
[2H4]6-keto-PGF1K, was added to the samples. After
forming the methoxyamine derivatives, the samples
were acidi¢ed and applied to a 100 mg octadecylsilyl
solid-phase extraction column (Alltech, Deer¢eld,
MI). The eluates were dried under a stream of nitro-
gen, then derivatized as penta£uorobenzyl esters.
This reaction mixture was dried under nitrogen and
applied to a thin layer chromatography plate
(LK6D, 60A Silica Gel Plates, Whatman, Clifton,
NJ). The mobile phase was 80% ethyl acetate and
20% heptane. The extracts were dried and trimethyl-
silyl ether derivatives were formed. The reaction mix-
ture was dried under nitrogen, the sample dissolved
in dodecane and analyzed by GC/MS (Fison MD-
800). The temperature program was 190^320‡C at
20‡C/min. The ions monitored were m/z 614 for 6-
keto-PGF1K, and m/z 618 for [2H4]6-keto-PGF1K.
2.9. MAP kinase
HUVEC were incubated in the absence or presence
of 5 Wg/ml SDF-1K in Medium 199 (Life Technolo-
gies, Gaithersburg, MD) containing 10 mM HEPES,
pH 7.4 for 1^15 min. The cells were then scraped and
extracted in bu¡er containing 1% Triton X-100, 10
mM Tris-HCl, pH 7.6, 50 mM NaCl, 3 mM sodium
pyrophosphate, 50 mM sodium £uoride, 1 mM so-
dium vanadate, and 1 mM phenylmethylsulfonyl £u-
oride at 4‡C for 15 min and clari¢ed by centrifuga-
tion. Samples containing equivalent amounts of
protein were analyzed by electrophoresis on SDS-
polyacrylamide gels (9% acrylamide), transferred to
PVDF, and probed with the antiphosphotyrosine
antibody 4G10 (UBI). Detection was by enhanced
chemiluminescence (New England Nuclear). The po-
sitions of MAPK p42/44 were con¢rmed by probing
with anti-MAPK R2 antibody (UBI) and correlated
with in-gel kinase assays.
2.10. Migration assay
Chemotaxis was assayed by using a modi¢ed Boy-
den chamber with 8 Wm pore size polycarbonate
PVP-free nucleopore ¢lters [51]. The ¢lters were pre-
pared by immersing them overnight in a solution of
100 Wg/ml gelatin in 0.1% acetic acid and then air-
dried. SDF-1 were added to the lower compartment
of the chamber. The endothelial cells were added to
the upper chamber in serum-free medium containing
0.1% BSA with or without the antibody 12G5. After
4 h, the ¢lters were stained with Di¡-Quick (Merz-
Dade, Dudigen, Switzerland) and the number of cells
that had migrated per 10 high-power ¢elds were
counted.
2.11. Matrigel assay
Early passage HUVEC were allowed to grow to
con£uence, washed twice in DPBS (Gibco-BRL) and
then incubated for at least 2 h in serum-depleted
medium (Medium 199, 2% fetal calf serum, 1 mM
glutamine, 100 U/ml penicillin and 100 Wg/ml strep-
tomycin). The cells were then released with trypsin,
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Fig. 1. Expression of CXCR4 on human endothelial cells. (A) Human coronary arteries were stained with the CXCR4 selective mono-
clonal antibody, 12G5 (upper panels) or an isotype-matched control antibody (lower panels). The panels on the right are higher mag-
ni¢cation views of the sections on the left. The arrowheads in the upper panels point towards positively stained endothelial cells at
the interface between the vessel lumen and wall. (B) Intact con£uent early passage human umbilical vein endothelial cells (HUVEC)
were stained with antibody 12G5 or the PAR1 monoclonal antibody, WEDE15. Permeabilized cells were stained with 12G5 or an
antibody to von Willebrand factor, which served as an endothelial cell-speci¢c marker. Representative ¢elds are shown from one of at
least three experiments. (C) Flow cytometry was used to detect the binding of 12G5, WEDE125 or the isotype-matched control anti-
body, D47.
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resuspended in Medium 199 at 5U104 cells/ml, and
then seeded on a 35-mm dish coated with a thin layer
of Matrigel (Collaborative Biomedical Products) ma-
trix. When indicated, antibody 12G5 (20 Wg/ml) was
added 30 min after the seeding the cells and SDF-1
(5 Wg/ml) was added 30 min later. Observation of the
cells continued for up to 8 h at 37‡C. Images were
captured at 200U magni¢cation using an Axiovert
405M microscope and a Hamamatsu chilled CCD
Twain 32 camera system.
2.12. Syncytia formation and assays for infection of
endothelial cells
Approximately 2U105 Sup-T1 cells that were
chronically infected with a CD4-independent strain
of HIV-2 (HIV-2/vcp) [34] were added to con£uent
or subcon£uent endothelial cells in 24-well plates
(Corning). After 48 and 72 h, cells were stained
with Di¡-Quick and evaluated for syncytia forma-
tion. When indicated, the HUVEC were preincu-
bated with monoclonal antibodies (20 Wg/ml) for 30
min at 37‡C before the addition of the infected cells.
Syncytia were quantitated by counting the number of
cells with s 3 nuclei in each well.
3. Results
3.1. Expression of CXCR4 on human endothelial cells
Although CXCR4has been reported to be ex-
pressed on human umbilical vein endothelial cells
(HUVEC) and on bovine aortic endothelial cells
[40,41,52], there is less information about its expres-
sion at other sites. In studies such as those shown in
Fig. 1, immunohistochemistry, £uorescence micros-
copy and £ow cytometry were used to examine ex-
pression of CXCR4 in human coronary arteries, iliac
arteries and HUVEC, and to compare the distribu-
tion of CXCR4 with another G protein-coupled re-
ceptor, the human thrombin receptor, PAR1. Fig.
1A shows sections of coronary arteries from hearts
removed at the time of transplantation. There is
prominent staining of the endothelial cells by the
CXCR4 antibody, 12G5 (arrowheads in the upper
two panels), but none elsewhere in the vascular
wall and no staining with an isotype-matched control
(lower panels). In the left panels of Fig. 1B, intact
HUVEC were stained with antibody 12G5 or the
PAR1-selective antibody, WEDE15. Many of the
cells show di¡use surface staining with 12G5. How-
ever, others within the same con£uent monolayer
show little or no surface staining. This heterogeneity
was observed consistently within individual prepara-
Fig. 2. Down-regulation of CXCR4 expression on endothelial
cells. (A) HUVEC were incubated with SDF-1K (10 Wg/ml for
10 min), thrombin (50 nM for 10 min) or PMA (100 nM for
30 min), then stained with the anti-CXCR4 antibody, 12G5, the
anti-PAR1 antibody, WEDE15, or the negative control anti-
body, D47. The results shown are the mean þ S.E.M. from four
studies expressed as a fraction of net antibody binding (detected
by £ow cytometry) in the absence of an agonist. The P values
shown were calculated by paired t-test comparing control and
treated cells. (B) Time course for loss of binding sites for the
anti-CXCR4 antibody 12G5 following the addition of 10 Wg/ml
SDF-1K (n = 3).
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tions from several di¡erent donors studied through
passage 8 and was also seen with iliac artery endo-
thelial cells (not shown). By comparison, the anti-
PAR1 antibody stained the surface of all of the HU-
VEC (Fig. 1B, lower left). This impression of a dif-
ference between the surface expression of the two
receptors was con¢rmed by £ow cytometry (Fig.
1C). There was a single symmetrical peak of
WEDE15 binding to PAR1 on the HUVEC, but
the binding of 12G5 to CXCR4 was broad and
asymmetric, indicating a range of expression levels
among the cells that were analyzed.
These results contrast with those obtained when
the endothelial cells were permeabilized before stain-
ing. In the two right panels in Fig. 1B, permeabilized
HUVEC were stained for CXCR4 and human von
Willebrand factor, a protein that is synthesized,
stored and secreted by endothelial cells. All of the
permeabilized cells bound both antibodies, con¢rm-
ing that they are endothelial cells and that CXCR4
synthesis is occurring in all of the cells. Collectively,
these results show that CXCR4 is expressed by arte-
rial and venous endothelial cells from at least three
di¡erent anatomic sites. The results also show that
the surface expression of CXCR4 can be more vari-
able than PAR1. Finally, the results also suggest that
the heterogeneity in surface expression is not due to
a failure of receptor synthesis, but to a failure to shift
the receptors to the cell surface or maintain them
there at steady state.
3.2. Receptor down-regulation following activation of
CXCR4 and PAR1
CXCR4 has been shown to become desensitized
following an initial response to SDF-1. Although
the precise mechanism has not been fully determined,
there is now ample evidence from studies in lym-
phoid cells and others that CXCR4, like other G
protein-coupled receptors, is subject to both phos-
phorylation and internalization following addition
of either SDF-1 or PMA, and that sites within the
C-terminus of the receptor and other cytoplasmic
domains are needed for this to occur [53^57]. There
is also evidence from a recent study in cells trans-
fected with a CXCR4-GFP (green £uorescent pro-
tein) chimera that CXCR4 also undergoes con-
stitutive turnover as well as agonist-induced
internalization [58]. At a separate level of regulation,
Gupta et al. [41] have shown that exposure of um-
bilical vein endothelial cells to cytokines such as
IFN-Q causes a reduction in CXCR4 mRNA levels
over a period of many hours.
We were interested in determining whether acti-
vated CXCR4 would become internalized in HU-
VEC and, in view of the results reported with
PMA, whether activation of unrelated receptors
that can stimulate phosphoinositide hydrolysis and
activate protein kinase C would also cause CXCR4
internalization as a form of receptor crosstalk. The
data in Fig. 2 compare the clearance of activated
Fig. 3. Cytosolic Ca2 increase in response to SDF-1. HUVEC were loaded with Fura-2 and then stimulated with either SDF-1K (10
Wg/ml or 1 WM) or thrombin (50 nM). The results shown are the mean þ S.E.M. of three studies expressed as the increment in cyto-
solic Ca2 that was observed after adding the agonist (vCa2). The inset shows the e¡ects of preincubating the cells with the anti-
CXCR4 antibody, 12G5 (50 Wg/ml).
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CXCR4 on endothelial cells with the clearance of
PAR1. PAR1 is known to be rapidly removed from
the surface of HUVEC following activation by
thrombin [48,59]. Incubating the endothelial cells
with SDF-1 caused a 60% decrease in the binding
of the CXCR4 antibody, 12G5, but had no e¡ect
on the binding of the PAR1 antibody, WEDE15
(Fig. 2A). A similar decrease in binding to SDF-1-
treated cells was seen with three other CXCR4 anti-
bodies (not shown). The reduction in 12G5 binding
sites was maximal within 10 min and was stable for
at least 1 h afterwards (Fig. 2B). Washing the cells to
remove the SDF-1 before addition of antibody 12G5
had no e¡ect on the results (not shown). Activating
the cells with thrombin for 10 min also caused a
decrease in 12G5 binding, as well as the expected
reduction in WEDE15 binding. The decrease in
WEDE15 binding caused by thrombin was similar
to the decrease in 12G5 binding caused by SDF-1
(about 60%). The decrease in 12G5 binding caused
by thrombin was smaller (about 20%), but ap-
proached the decrease in 12G5 binding caused by
PMA.
These results suggest that CXCR4 is subject to the
same post-activation clearance on endothelial cells
that it is on lymphoid cells. The results also suggest
that there are heterologous e¡ects on CXCR4 as
well, with crosstalk between receptors (in this case
PAR1) able to cause at least a small decrease in
CXCR4 expression that occurs more rapidly than
can be accounted for by an e¡ect on receptor syn-
thesis. The biological relevance of this latter e¡ect
remains to be established.
Fig. 5. Activation of MAPK by SDF-1. Con£uent HUVEC were stimulated with 5 Wg/ml SDF-1 for 1^15 min, after which lysates
were prepared and subjected to gel electrophoresis. (A) Western blot with an antibody that recognizes ERK-1 and ERK-2. In addition
to showing the phosphorylated and non-phosphorylated forms of the two proteins, this part of the ¢gure also shows that the same
amount of protein has been loaded into each lane. (B) The same immunoblot re-probed with an antiphosphotyrosine antibody. The
results shown are representative of three such studies. pERK-1 and -2 refer to the phosphorylated forms of these proteins.
Fig. 4. SDF-1 stimulates PGI2 formation in endothelial cells.
Early passage HUVEC were incubated with 5 Wg/ml (500 nM)
SDF-1 for the times that are shown. Released PGI2 was de-
tected as its stable metabolite, 6-keto-PGF1K. The results shown
for SDF-1 are the mean from two studies. The result shown for
thrombin is the mean of three measurements taken 5 min after
the addition of 50 nM thrombin. Note the di¡erence in the or-
dinate in the two parts of the ¢gure.
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3.3. Consequences of CXCR4 activation in endothelial
cells
To better understand the e¡ects of CXCR4 activa-
tion on endothelial cells, we tested whether SDF-1
would cause an increase in the cytosolic Ca2 con-
centration, stimulate prostaglandin formation, and
activate ras-related pathways to phosphorylate
MAP kinases. Inhibition by antibody 12AG5 was
used to determine whether the response to SDF-1
involved CXCR4. Inhibition by pertussis toxin was
used to determine whether the response was medi-
ated by members of the Gi family of G proteins. In
keeping with previous reports [40,41], we found that
SDF-1 causes, at best, a modest increase in the cy-
tosolic Ca2 concentration in HUVEC loaded with
Fura-2 (Fig. 3). This increase was reduced when the
cells were preincubated with 12G5 (inset to Fig. 3) or
pertussis toxin (not shown). At maximally e¡ective
concentrations of SDF-1 (10 Wg/ml or 1 WM), the
increase in cytosolic Ca2 was substantially smaller
than when the cells were stimulated with thrombin
(mean vCa2 71 þ 6 nM vs. 328 þ 27 nM). This dif-
ference in response to SDF-1 and thrombin is not
unique to endothelial cells, but has also been ob-
served in transfected HEK-293 cells [60].
Since the increase in cytosolic Ca2 caused by
SDF-1 was modest compared to the response to
thrombin, we asked whether downstream e¡ects
that can be evoked with thrombin also occur in HU-
VEC following addition of SDF-1. PGI2 formation is
characteristic of activated endothelial cells and plays
an important role in their ability to suppress un-
necessary platelet activation. Synthesis of PGI2 indi-
cates that phospholipase A2 has been activated and
arachidonate released from membrane phospholip-
ids. Fig. 4 shows the time course of PGI2 formation
(measured as 6-keto-PGF1K) when HUVEC were in-
cubated with SDF-1. Despite the small increase in
Ca2, SDF-1 caused a substantial increase in 6-
keto-PGF1K that peaked within approximately 10
min. The mean peak increase at 10 min was half
that seen after 5 min with thrombin and was inhib-
ited by preincubating the cells with pertussis toxin
(not shown). Similar kinetics were observed for phos-
phorylation of the MAP kinases, ERK1 and ERK2,
which also occurred in the SDF-1-stimulated cells. In
the experiment shown in Fig. 5, HUVEC were incu-
bated with SDF-1 for up to 15 min. Phosphorylation
of both isoforms was detectable within 3 min (Fig.
5B) and was prevented by preincubating the cells
with pertussis toxin (not shown).
3.4. Migration and formation of capillary-like
structures
CXCR4 knockout studies suggest that activation
of CXCR4 by SDF-1 may play a role in angiogene-
sis, particularly at selected sites [11]. Because of that,
we tested the ability of SDF-1 to cause endothelial
cell migration and to stimulate formation of capil-
lary-like structures on a collagen matrix. In the stud-
ies shown in Fig. 6, umbilical vein endothelial cells
were exposed to SDF-1 in a Boyden chamber. A
dose-related increase in migration was observed
with the extent of migration at high SDF-1 concen-
trations (10 Wg/ml or 1 WM) similar to that evoked by
Fig. 6. Endothelial cell migration in response to SDF-1. Either
SDF-1K at the concentrations shown or bFGF (1 ng/ml) was
added to the lower compartment of a Boyden chamber. HU-
VEC, resuspended in serum-free medium containing 0.1% BSA,
were added to the upper chamber which was separated from
the lower by a porous ¢lter. Chemotaxis was allowed to occur
for 4 h and was quantitated by counting the number of cells
per 10 high-power ¢elds that had migrated through the ¢lter.
The data are expressed as fold-increase over baseline migration
determined in the absence of chemoattractants (mean þ S.E.M.
from three to ¢ve experiments). The average number of migrat-
ing cells observed in the absence of stimulus was approximately
16 cells per high-power ¢eld. The inset shows the results of two
experiments in which the cells were preincubated with antibody
12G5 (50 Wg/ml) prior to exposure to 10 Wg/ml SDF-1.
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1 ng/ml bFGF. Preincubating the cells with antibody
12G5 (50 Wg/ml) inhibited migration in response to
SDF-1 (inset to Fig. 6), although it had no e¡ect on
the response to bFGF (not shown).
Thus, at high concentrations, SDF-1 acts as a che-
moattractant for endothelial cells and this response
also appears to be mediated by CXCR4. In the study
shown in Fig. 7, we asked whether SDF-1 would also
stimulate formation of capillary-like structures on a
collagen matrix (Matrigel). HUVEC that had been
serum-starved for 2 h were incubated with 5 Wg/ml
SDF-1. The photographs shown were taken approx-
imately 6 h after the addition of SDF-1. In the ab-
Fig. 8. Syncytium formation. Low- and high-power views of
HUVEC incubated for 48 h either (A) alone (Control) or with
Sup-T1 infected with (B) HIV-2/vcp (VCP) alone, (C) HIV-2/
vcp plus 20 Wg/ml anti-CXCR4 antibody 44717
(VCP+KCXCR4) or (D) HIV-2/vcp plus 20 Wg/ml anti-CD4
antibody 19 (VCP+KCD4). The results shown are representative
of those obtained in three similar experiments.
Fig. 7. Morphological responses to SDF-1. HUVEC were de-
pleted of serum for 2 h and then seeded on Matrigel as de-
scribed in Section 2. Where indicated, the cells were preincu-
bated for 30 min with 20 Wg/ml antibody 12G5 before adding
5 Wg/ml SDF-1. The results shown were photographed 6 h after
addition of the SDF-1 and are representative of four such ex-
periments.
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sence of antibody 12G5, SDF-1 caused a striking
increase in capillary-like structures compared to cells
that were incubated under identical conditions, but
without SDF-1. Preincubating the cells with antibody
12G5 reduced this response to levels that resembled
untreated cells.
3.5. Utilization of endothelial cell CXCR4 by HIV
The data presented thus far show that CXCR4 is a
functional receptor on human endothelial cells that is
capable of evoking biologically relevant responses
when activated by SDF-1. We also asked whether
CXCR4 expressed on endothelial cells could function
as a receptor for HIV. T-cell tropic isolates of HIV-1
and HIV-2 have been shown to infect CD4 lympho-
cytes by interacting with both CD4 and CXCR4 [61].
However, some CD4-independent variants of HIV-1
and HIV-2 have been described that can also utilize
CXCR4 as a primary receptor in the absence of CD4
[34,62,63]. Because endothelial cells do not express
CD4 [42^45] (a ¢nding that we con¢rmed), we deter-
mined whether one of these isolates, HIV-2/vcp,
could utilize CXCR4 on endothelial cells as a recep-
tor. As described previously [34], HIV-2/vcp has an
expanded host range in vitro and is capable of in-
fecting several CD4-negative T, B and non-lymphoid
cell lines. To perform this evaluation we utilized fu-
sion assays in which HUVEC were cultured with
HIV-2/vcp-infected lymphoid cells and monitored
for syncytia formation. Fusion of infected and unin-
fected cells by HIV is dependent upon a speci¢c in-
teraction between the viral envelope glycoprotein and
cellular receptors, and re£ects events that are similar
to those required for viral entry [64].
When HUVEC were incubated with HIV-2/vcp-in-
fected Sup-T1 cells for 48^72 h, extensive syncytia
formation was observed (Fig. 8). There were no mul-
tinucleated cells when HUVEC were cultured alone
or with uninfected SupT1 cells. Syncytia formation
was inhibited s 95% by preincubating HUVEC with
anti-CXCR4 antibodies 44717 (Fig. 8C) and 44701
(not shown), and s 80% by antibody 12G5 (not
shown). An anti-CD4 antibody that was included
as a control had little or no e¡ect (Fig. 8D). Thus
endothelial cell CXCR4 can serve as an HIV recep-
tor, at least for some CXCR4-tropic isolates that do
not require CD4.
4. Discussion
There has recently been a growing interest in the
role of CXCR4 on endothelial cells, in part because
of the disorders of cardiogenesis and angiogenesis
observed in mice lacking the receptor or its ligand
[11^13], and in part because of the possibility that
endothelial cell CXCR4, acting as a viral receptor,
helps to support the spread of HIV. Although
CXCR4 was originally identi¢ed in lymphocytes
and monocytes, there is now increasing evidence
that the receptor is also expressed in a variety of
other cells and tissues. In the present studies, we
have examined the expression of CXCR4 on human
endothelial cells from both the arterial and venous
circulation, observed the clearance of the receptor
from the cell surface following the addition of
SDF-1 and thrombin, tested the range of responses
elicited from endothelial cells by SDF-1, and deter-
mined whether endothelial cell CXCR4 can serve as
an HIV receptor.
Using CXCR4-selective antibodies, we found that
CXCR4 is present not only on umbilical vein endo-
thelial cells, but also on iliac and coronary artery
endothelial cells. Interestingly, there was a striking
discordance between the number of cells that ex-
pressed CXCR4 and the number of cells on which
the receptor could be detected on the cell surface.
For both the umbilical vein endothelial cells and
the iliac artery-derived cells, surface expression of
CXCR4 was far more heterogeneous than was ex-
pression of the thrombin receptor, PAR1.
G protein-coupled receptors, including chemokine
receptors, are subject to a variety of regulatory pro-
cesses that limit their duration of activity and can
lead to rapid down-regulation of surface expression.
This typically involves phosphorylation of the cyto-
plasmic domains of the receptors by G protein-
coupled receptor kinases (GRKs) and, in some cases,
protein kinase C. In cells other than endothelial cells,
it has been observed that CXCR4 becomes desensi-
tized and phosphorylated following the addition of
SDF-1 or the phorbol ester, PMA [53^58]. We found
that SDF-1 caused a rapid decrease in the amount of
CXCR4 detectable on the surface of intact HUVEC
that was maximal within 10 min and persisted for at
least 1 h. PMA caused a smaller decrease in CXCR4
expression than did thrombin. This suggests that ex-
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posure of endothelial cells to thrombin, such as
might occur at sites of vascular injury, may a¡ect
CXCR4 expression levels. There was no correspond-
ing decrease in PAR1 expression when CXCR4 was
activated. Whether the decrease in CXCR4 caused by
thrombin is due to the activation of protein kinase C
remains to be determined, as does its biological im-
pact.
Activation of CXCR4 in lymphoid cells (e.g. refer-
ence [65]) and endothelial cells [40,41] causes a tran-
sient increase in the cytosolic Ca2 concentration.
Compared to other agonists, such as thrombin, the
magnitude of this increase is relatively modest (Fig.
3). In cells other than platelets, thrombin typically
stimulates phospholipase C and increases cytosolic
Ca2 via pertussis toxin-resistant members of the
Gq family of G proteins. As found in the present
study, responses to SDF-1 are typically pertussis tox-
in-sensitive. Despite producing only a small increase
in cytosolic Ca2, SDF-1 was able to stimulate PGI2
formation, and increase ERK1 and ERK2 phosphor-
ylation (Figs. 4 and 5). PGI2 formation is particu-
larly notable since secreted PGI2 interacts with re-
ceptors on the surface of human platelets, raising
cAMP levels and inhibiting platelet responses to ag-
onists. Along with NO release and surface ecto-
ADPase activity, this provides a mechanism by
which endothelial cells limit platelet activation in
vivo and shows for the ¢rst time that SDF-1 can
participate in this process.
In addition to these biochemical markers of endo-
thelial cell activation, SDF-1 has also proved to be
chemotactic for endothelial cells, causing migration
in a Boyden chamber assay and inducing formation
of capillary-like structures on a collagen matrix
(reference [41] and Figs. 6 and 7). These responses
were comparable in extent to those evoked by bFGF
or TNF-K, and could be inhibited by preincubating
the cells with an anti-CXCR4 antibody. It is tempt-
ing to relate the ability of SDF-1 to elicit these re-
sponses in vitro to the observed localized defects in
angiogenesis observed in the CXCR4 knockout mice.
Finally, our results also show that CXCR4 on en-
dothelial cells can function pathologically as a recep-
tor for a CD4-independent/CXCR4 tropic variant of
HIV-2. Although this variant was adapted for
growth in human cell lines and may have acquired
properties di¡erent from those that occur in infected
humans, several studies in vitro [66^69] and in vivo
[68,70,71], have suggested that endothelial cells from
humans and non-human primates are infectable by
particular isolates of HIV and SIV in a CD4-inde-
pendent manner. Moreover, Edinger et al. [72] re-
cently demonstrated that isolates of SIV that caused
neurological disease in rhesus macaques could infect
brain-derived endothelial cells by using CCR5, rais-
ing the possibility that CD4-independent infection of
these cells could be relevant to neuropathogenesis.
Although our study demonstrated that HIV-2/vcp
could utilize HUVEC CXCR4 to induce syncytia
we were unable to show productive infection when
HUVEC were incubated with cell free HIV-2/vcp
(unpublished observations). Nonetheless, these ¢nd-
ings indicate that CXCR4 can, under some circum-
stances, function as an HIV receptor, and further
studies on the ability of CXCR4-tropic HIVs to
bind and enter endothelial cells are warranted.
In conclusion, these ¢ndings highlight a growing
body of evidence on the importance of SDF-1 and
CXCR4 in vascular biology where the receptor/
ligand pair appears able to play an important role
in angiogenesis and endothelial cell responses to
injury and in£ammation. The results show that the
signaling pathways that are activated in endothelial
cells when SDF-1 binds to CXCR4 are able to evoke
biologically relevant responses. The results also
show that at least one virus can use the CXCR4
present on the surface of endothelial cells as a recep-
tor and raises the possibility that some CXCR4-
tropic viruses or their envelope glycoproteins could
contribute directly or indirectly to endothelial cell
pathology.
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